Hydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxModified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/in Not PCa related/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/in CRISPR, Not PCa related, Preclinical Research/by MaxMistery Solved: How Diabetes Drug Metformin Lowers Blood Sugar by Targeting Cell’s Powerhouse
/in Not PCa related/by MaxA New Hope for Hard-to-Treat Cancers: a New TACC3 Inhibitor
/in Clinical Trial, Not PCa related/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/in Not PCa related, Preclinical Research/by MaxAI designed cancer drug gets FDA approval for clinical trials
/in Artificial Intelligence, Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR September 14, 2026
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026